Evidence map›Paper›PMID 36909742›Full record

ArticleRSC advances2023

Controlling the crystal structure of succinic acid

Aysu Ceren Okur, Philipp Erni, Lahoussine Ouali, Daniel Benczedi, Esther Amstad

Abstract read
In one paragraph

Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aysu Ceren OkurSoft Materials Laboratory, Institute of Materials, École Polytechnique Fédérale de Lausanne (EPFL) Lausanne 1015 Switzerland esther.amstad@epfl.ch.
Philipp ErniFirmenich SA, Corporate R&D Division PO Box 239 CH-1211 Geneva 8 Switzerland.ORCID https://orcid.org/0000-0002-4241-0898
Lahoussine OualiFirmenich SA, Corporate R&D Division PO Box 239 CH-1211 Geneva 8 Switzerland.
Daniel BenczediFirmenich SA, Corporate R&D Division PO Box 239 CH-1211 Geneva 8 Switzerland.
Esther AmstadSoft Materials Laboratory, Institute of Materials, École Polytechnique Fédérale de Lausanne (EPFL) Lausanne 1015 Switzerland esther.amstad@epfl.ch.ORCID https://orcid.org/0000-0002-9491-1010

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many properties of materials, including their dissolution kinetics, hardness, and optical appearance, depend on their structure. Unfortunately, it is often difficult to control the structure of low molecular weight organic compounds that have a high propensity to crystallize if they are formulated from solutions wherein they have a high mobility. This limitation can be overcome by formulating these compounds within small airborne drops that rapidly dry, thereby limiting the time molecules have to arrange into the thermodynamically most stable phase. Such drops can be formed with a surface acoustic wave (SAW)-based spray-drier. In this paper, we demonstrate that the structure of a model low molecular weight compound relevant to applications in pharmacology and food, succinic acid, can be readily controlled with the supersaturation rate. Succinic acid particles preserve the metastable structure over at least 3 months if the initial succinic acid concentration is below 2% of its saturation concentration such that the supersaturation rate is high. We demonstrate that also the stability of the metastable phases against their transformation into the most stable phase increases with decreasing initial solute concentration and hence with increasing supersaturation rate of the spray-dried solution. These insights open up new opportunities to control the crystal structure and therefore properties of low molecular weight compounds that have a high propensity to crystallize.

Identifiers

PMID36909742
PMCPMC9993402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.